<DOC>
	<DOC>NCT00978198</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of ASP1517 after single or multiple oral administration in healthy non-elderly adult male subjects.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers</brief_title>
	<detailed_description>The study consists of two parts, single and multiple dose. Within each part participants will be randomized to either ASP1517 or placebo.</detailed_description>
	<criteria>Body weight: ≥50.0 kg, &lt;80.0 kg BMI: ≥18.5 kg/m2, &lt;25.0 kg/m2 Eligible, as judged by the investigator/subinvestigator based on the results of physical examinations (subjective symptoms and objective findings) and all tests obtained at screening and up to the timing immediately before study medication Supine blood pressure: Systolic blood pressure ≥90 mmHg, ≤130 mmHg; Diastolic blood pressure ≤85 mmHg Pulse rate at rest in supine position: ≥40 bpm, &lt;100 bpm Received any investigational drugs in other clinical or postmarketing studies within 120 days before the screening assessment Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment Received medication within 7 days before hospital admission or is scheduled to receive medication History of drug allergies Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before the study Excessive smoking or drinking habit (measure of "excessive": alcohol: 45 g/day, smoking: 20 cigarettes/day)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety and tolerability</keyword>
	<keyword>Plasma concentration</keyword>
	<keyword>ASP1517</keyword>
	<keyword>FG-4592</keyword>
</DOC>